Steroid receptor-associated immunophilins: A gateway to steroid signalling

Clinical Biochemist Reviews

Volumn 36, Issue 2, 2015, Pages 31-52

  Ratajczak, Thomas ^a,b   Cluning, Carmel ^a,b   Ward, Bryan K ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938770071     PISSN: 01598090     EISSN: 18380212     Source Type: Journal    
DOI: None     Document Type: Review

References (212)

1. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-64.
2. Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta 2010;1803:641-9.
3. Picard D. Chaperoning steroid hormone action. Trends Endocrinol Metab 2006;17:229-35.
4. Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004;16:857-72.
5. Ratajczak T, Ward BK, Cluning C, Allan RK. Cyclophilin 40: an Hsp90-cochaperone associated with apo-steroid receptors. Int J Biochem Cell Biol 2009;41:1652-5.
6. Ratajczak T, Ward BK, Minchin RF. Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem 2003;3:1348-57.
7. Sanchez ER. Chaperoning steroidal physiology: lessons from mouse genetic models of Hsp90 and its cochaperones. Biochim Biophys Acta 2012;1823:722-9.
8. Smith DF. Tetratricopeptide repeat cochaperones in steroid receptor complexes. Cell Stress Chaperones 2004;9:109-21.
9. Smith DF, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol 2008;22:2229-40.
10. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006;440:1013-7.
11. Meyer P, Prodromou C, Liao C, Hu B, Roe SM, Vaughan CK, et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 2004;23:1402-10.
12. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94.
13. McLaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol 2002;315:787-98.
14. Prodromou C, Siligardi G, O'Brien R, Woolfson DN, Regan L, Panaretou B, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J 1999;18:754-62.
15. Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J Biol Chem 2003;278:10328-33.
16. Richter K, Walter S, Buchner J. The Co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J Mol Biol 2004;342:1403-13.
17. Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J Biol Chem 2004;279:51989-98.
18. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18.
19. Li J, Richter K, Reinstein J, Buchner J. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle. Nat Struct Mol Biol 2013;20:326-31.
20. Tai PK, Maeda Y, Nakao K, Wakim NG, Duhring JL, Faber LE. A 59-kilodalton protein associated with progestin, estrogen, androgen, and glucocorticoid receptors. Biochemistry 1986;25:5269-75.
21. Peattie DA, Harding MW, Fleming MA, DeCenzo MT, Lippke JA, Livingston DJ, et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. Proc Natl Acad Sci U S A 1992;89:10974-8.
22. Ratajczak T, Carrello A, Mark PJ, Warner BJ, Simpson RJ, Moritz RL, et al. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). J Biol Chem 1993;268:13187-92.
23. Davis TL, Walker JR, Campagna-Slater V, Finerty PJ Jr, Paramanathan R, Bernstein G, et al. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol 2010;8:e1000439.
24. Nair SC, Rimerman RA, Toran EJ, Chen S, Prapapanich V, Butts RN, et al. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol Cell Biol 1997;17:594-603.
25. Smith DF, Albers MW, Schreiber SL, Leach KL, Deibel MR Jr. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. J Biol Chem 1993;268:24270-3.
26. Owens-Grillo JK, Hoffmann K, Hutchison KA, Yem AW, Deibel MR Jr, Handschumacher RE, et al. The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J Biol Chem 1995;270:20479-84.
27. Radanyi C, Chambraud B, Baulieu EE. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. Proc Natl Acad Sci U S A 1994;91:11197-201.
28. Ratajczak T, Carrello A. Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J Biol Chem 1996;271:2961-5.
29. Silverstein AM, Galigniana MD, Chen M-S, Owens-Grillo JK, Chinkers M, Pratt WB. Protein phosphatase 5 is a major component of glucocorticoid receptor. hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem 1997;272:16224-30.
30. Chen M-S, Silverstein AM, Pratt WB, Chinkers M. The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem 1996;271:32315-20.
31. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997;18:306-60.
32. Mark PJ, Ward BK, Kumar P, Lahooti H, Minchin RF, Ratajczak T. Human cyclophilin 40 is a heat shock protein that exhibits altered intracellular localization following heat shock. Cell Stress Chaperones 2001;6:59-70.
33. Yokoi H, Kondo H, Furuya A, Hanai N, Ikeda JE, Anazawa H. Characterization of cyclophilin 40: highly conserved protein that directly associates with Hsp90. Biol Pharm Bull 1996;19:506-11.
34. Davies TH, Ning Y-M, Sánchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 2002;277:4597-600.
35. Sinars CR, Cheung-Flynn J, Rimerman RA, Scammell JG, Smith DF, Clardy J. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc Natl Acad Sci U S A 2003;100:868-73.
36. Taylor P, Dornan J, Carrello A, Minchin RF, Ratajczak T, Walkinshaw MD. Two structures of cyclophilin 40: folding and fidelity in the TPR domains. Structure 2001;9:431-8.
37. Wu B, Li P, Liu Y, Lou Z, Ding Y, Shu C, et al. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci U S A 2004;101:8348-53.
38. Cioffi DL, Hubler TR, Scammell JG. Organization and function of the FKBP52 and FKBP51 genes. Curr Opin Pharmacol 2011;11:308-13.
39. Yang J, Roe SM, Cliff MJ, Williams MA, Ladbury JE, Cohen PT, et al. Molecular basis for TPR domainmediated regulation of protein phosphatase 5. EMBO J 2005;24:1-10.
40. Chen MX, Cohen PT. Activation of protein phosphatase 5 by limited proteolysis or the binding of polyunsaturated fatty acids to the TPR domain. FEBS Lett 1997;400:136-40.
41. Ramsey AJ, Chinkers M. Identification of potential physiological activators of protein phosphatase 5. Biochemistry 2002;41:5625-32.
42. Skinner J, Sinclair C, Romeo C, Armstrong D, Charbonneau H, Rossie S. Purification of a fatty acidstimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5. J Biol Chem 1997;272:22464-71.
43. Barent RL, Nair SC, Carr DC, Ruan Y, Rimerman RA, Fulton J, et al. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol Endocrinol 1998;12:342-54.
44. Ratajczak T, Hlaing J, Brockway MJ, Hähnel R. Isolation of untransformed bovine estrogen receptor without molybdate stabilization. J Steroid Biochem 1990;35:543-53.
45. Silverstein AM, Galigniana MD, Kanelakis KC, Radanyi C, Renoir J-M, Pratt WB. Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein. J Biol Chem 1999;274:36980-6.
46. Riggs DL, Roberts PJ, Chirillo SC, Cheung-Flynn J, Prapapanich V, Ratajczak T, et al. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J 2003;22:1158-67.
47. Banerjee A, Periyasamy S, Wolf IM, Hinds TD Jr, Yong W, Shou W, et al. Control of glucocorticoid and progesterone receptor subcellular localization by the ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat proteins. Biochemistry 2008;47:10471-80.
48. Dean DA, Urban G, Aragon IV, Swingle M, Miller B, Rusconi S, et al. Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. BMC Cell Biol 2001;2:6.
49. Gallo LI, Ghini AA, Piwien Pilipuk G, Galigniana MD. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity. Biochemistry 2007;46:14044-57.
50. Echeverría PC, Mazaira G, Erlejman A, Gomez-Sanchez C, Piwien Pilipuk G, Galigniana MD. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol Cell Biol 2009;29:4788-97.
51. Galigniana MD, Erlejman AG, Monte M, Gomez-Sanchez C, Piwien-Pilipuk G. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol Cell Biol 2010;30:1285-98.
52. Galigniana MD, Echeverría PC, Erlejman AG, Piwien-Pilipuk G. Role of molecular chaperones and TPRdomain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore. Nucleus 2010;1:299-308.
53. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot-Applanat M, Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J 1991;10:3851-9.
54. Madan AP, DeFranco DB. Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc Natl Acad Sci U S A 1993;90:3588-92.
55. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2000;141:4107-13.
56. Reynolds PD, Ruan Y, Smith DF, Scammell JG. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J Clin Endocrinol Metab 1999;84:663-9.
57. Scammell JG, Denny WB, Valentine DL, Smith DF. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen Comp Endocrinol 2001;124:152-65.
58. Denny WB, Prapapanich V, Smith DF, Scammell JG. Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 2005;146:3194-201.
59. Davies TH, Ning YM, Sánchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8.
60. Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992;256:1315-8.
61. Chen S, Sullivan WP, Toft DO, Smith DF. Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones 1998;3:118-29.
62. Cheung-Flynn J, Roberts PJ, Riggs DL, Smith DF. C-terminal sequences outside the tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to Hsp90. J Biol Chem 2003;278:17388-94.
63. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301-23.
64. Ramsey AJ, Russell LC, Whitt SR, Chinkers M. Overlapping sites of tetratricopeptide repeat protein binding and chaperone activity in heat shock protein 90. J Biol Chem 2000;275:17857-62.
65. Allan RK, Mok D, Ward BK, Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem 2006;281:7161-71.
66. Mok D, Allan RK, Carrello A, Wangoo K, Walkinshaw MD, Ratajczak T. The chaperone function of cyclophilin 40 maps to a cleft between the prolyl isomerase and tetratricopeptide repeat domains. FEBS Lett 2006;580:2761-8.
67. Duina AA, Marsh JA, Kurtz RB, Chang H-C, Lindquist S, Gaber RF. The peptidyl-prolyl isomerase domain of the CyP-40 cyclophilin homolog Cpr7 is not required to support growth or glucocorticoid receptor activity in Saccharomyces cerevisiae. J Biol Chem 1998;273:10819-22.
68. Mayr C, Richter K, Lilie H, Buchner J. Cpr6 and Cpr7, two closely related Hsp90-associated immunophilins from Saccharomyces cerevisiae, differ in their functional properties. J Biol Chem 2000;275:34140-6.
69. Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J 2006;25:367-76.
70. Garabedian MJ, Yamamoto KR. Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. Mol Biol Cell 1992;3:1245-57.
71. Fang Y, Fliss AE, Robins DM, Caplan AJ. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996;271:28697-702.
72. Picard D, Khursheed B, Garabedian MJ, Fortin MG, Lindquist S, Yamamoto KR. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 1990;348:166-8.
73. Duina AA, Chang H-C, Marsh JA, Lindquist S, Gaber RF. A cyclophilin function in Hsp90-dependent signal transduction. Science 1996;274:1713-5.
74. Duina AA, Marsh JA, Gaber RF. Identification of two CyP-40-like cyclophilins in Saccharomyces cerevisiae, one of which is required for normal growth. Yeast 1996;12:943-52.
75. Warth R, Briand PA, Picard D. Functional analysis of the yeast 40 kDa cyclophilin Cyp40 and its role for viability and steroid receptor regulation. Biol Chem 1997;378:381-91.
76. Pirkl F, Buchner J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J Mol Biol 2001;308:795-806.
77. Periyasamy S, Hinds T Jr, Shemshedini L, Shou W, Sanchez ER. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010;29:1691-701.
78. Hubler TR, Scammell JG. Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 2004;9:243-52.
79. Paakinaho V, Makkonen H, Jääskeläinen T, Palvimo JJ. Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol 2010;24:511-25.
80. Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 2005;280:4609-16.
81. Fuller PJ, Smith BJ, Rogerson FM. Cortisol resistance in the New World revisited. Trends Endocrinol Metab 2004;15:296-9.
82. Cluning C, Ward BK, Rea SL, Arulpragasam A, Fuller PJ, Ratajczak T. The helix 1-3 loop in the glucocorticoid receptor LBD is a regulatory element for FKBP cochaperones. Mol Endocrinol 2013;27:1020-35.
83. Cheung-Flynn J, Prapapanich V, Cox MB, Riggs DL, Suarez-Quian C, Smith DF. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 2005;19:1654-66.
84. Tranguch S, Cheung-Flynn J, Daikoku T, Prapapanich V, Cox MB, Xie H, et al. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A 2005;102:14326-31.
85. Yang Z, Wolf IM, Chen H, Periyasamy S, Chen Z, Yong W, et al. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor A isoform. Mol Endocrinol 2006;20:2682-94.
86. Riggs DL, Cox MB, Tardif HL, Hessling M, Buchner J, Smith DF. Noncatalytic role of the FKBP52 peptidylprolyl isomerase domain in the regulation of steroid hormone signaling. Mol Cell Biol 2007;27:8658-69.
87. Wang Z, Chen W, Kono E, Dang T, Garabedian MJ. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol Endocrinol 2007;21:625-34.
88. Ikeda K, Ogawa S, Tsukui T, Horie-Inoue K, Ouchi Y, Kato S, et al. Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription. Mol Endocrinol 2004;18:1131-43.
89. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-9.
90. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007;275:43-61.
91. Hinds TD Jr, Stechschulte LA, Cash HA, Whisler D, Banerjee A, Yong W, et al. Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-? (PPAR?). J Biol Chem 2011;286:42911-22.
92. Sumanasekera WK, Tien ES, Davis JW 2nd, Turpey R, Perdew GH, Vanden Heuvel JP. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferatoractivated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry 2003;42:10726-35.
93. Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, et al. Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem 2007;282:5026-36.
94. Hong J, Kim ST, Tranguch S, Smith DF, Dey SK. Deficiency of co-chaperone immunophilin FKBP52 compromises sperm fertilizing capacity. Reproduction 2007;133:395-403.
95. Chen H, Yong W, Hinds TD Jr, Yang Z, Zhou Y, Sanchez ER, et al. Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. J Biol Chem 2010;285:27776-84.
96. Tranguch S, Smith DF, Dey SK. Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online 2006;13:651-60.
97. Tranguch S, Wang H, Daikoku T, Xie H, Smith DF, Dey SK. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest 2007;117:1824-34.
98. Greig KT, Carotta S, Nutt SL. Critical roles for c-Myb in hematopoietic progenitor cells. Semin Immunol 2008;20:247-56.
99. Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003;4,CD003511.
100. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
101. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99.
102. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002;83:149-55.
103. Jackson KS, Brudney A, Hastings JM, Mavrogianis PA, Kim JJ, Fazleabas AT. The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity. Reprod Sci 2007;14:137-50.
104. Hirota Y, Tranguch S, Daikoku T, Hasegawa A, Osuga Y, Taketani Y, et al. Deficiency of immunophilin FKBP52 promotes endometriosis. Am J Pathol 2008;173:1747-57.
105. Yang H, Zhou Y, Edelshain B, Schatz F, Lockwood CJ, Taylor HS. FKBP4 is regulated by HOXA10 during decidualization and in endometriosis. Reproduction 2012;143:531-8.
106. Ward BK, Mark PJ, Ingram DM, Minchin RF, Ratajczak T. Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat 1999;58:267-80.
107. Ratajczak T, Woollatt E, Kumar P, Ward BK, Minchin RF, Baker E. Cyclophilin 40 (PPID) gene map position 4q31.3. Chromosome Res 1997;5:151.
108. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:5-12.
109. Ward BK, Kumar P, Turbett GR, Edmondston JE, Papadimitriou JM, Laing NG, et al. Allelic loss of cyclophilin 40, an estrogen receptor-associated immunophilin, in breast carcinomas. J Cancer Res Clin Oncol 2001;127:109-15.
110. Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2011;104:19-23.
111. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009;16:259-66.
112. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 2005;173:1772-7.
113. Hubler TR, Denny WB, Valentine DL, Cheung-Flynn J, Smith DF, Scammell JG. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 2003;144:2380-7.
114. Magee JA, Chang LW, Stormo GD, Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006;147:590-8.
115. Makkonen H, Kauhanen M, Paakinaho V, Jääskeläinen T, Palvimo JJ. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res 2009;37:4135-48.
116. Fabian AK, März A, Neimanis S, Biondi RM, Kozany C, Hausch F. InterAKTions with FKBPs-mutational and pharmacological exploration. PLoS One 2013;8:e57508.
117. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, et al. A physical and functional map of the human TNF-a/NF-? B signal transduction pathway. Nat Cell Biol 2004;6:97-105.
118. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
119. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42.
120. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79.
121. Golden T, Aragon IV, Rutland B, Tucker JA, Shevde LA, Samant RS, et al. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim Biophys Acta 2008;1782:259-70.
122. Urban G, Golden T, Aragon IV, Scammell JG, Dean NM, Honkanen RE. Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively. J Biol Chem 2001;276:27638-46.
123. Zhang Y, Leung DY, Nordeen SK, Goleva E. Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation. J Biol Chem 2009;284:24542-52.
124. Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 2007;148:4716-26.
125. Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007;121:2596-605.
126. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, et al. Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: therapeutic implications for castrationresistant prostate cancer. Cancer Res 2007;67:5033-41.
127. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
128. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000;60:6134-41.
129. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718-23.
130. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
131. Ni L, Yang C-S, Gioeli D, Frierson H, Toft DO, Paschal BM. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol 2010;30:1243-53.
132. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
133. Warrier M, Hinds TD Jr, Ledford KJ, Cash HA, Patel PR, Bowman TA, et al. Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. Endocrinology 2010;151:3225-36.
134. Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V. Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012;2012:525093.
135. Grankvist N, Honkanen RE, Sjöholm Å, Ortsäter H. Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain. FEBS Lett 2013;587:3869-74.
136. Fransson L, Rosengren V, Saha TK, Grankvist N, Islam T, Honkanen RE, et al. Mitogen-activated protein kinases and protein phosphatase 5 mediate glucocorticoid-induced cytotoxicity in pancreatic islets and ß-cells. Mol Cell Endocrinol 2014;383:126-36.
137. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463-75.
138. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319-25.
139. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009;34(Suppl 1):S186-95.
140. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008;63:1103-10.
141. Shibuya N, Suzuki A, Sadahiro R, Kamata M, Matsumoto Y, Goto K, et al. Association study between a functional polymorphism of FK506-binding protein 51 (FKBP5) gene and personality traits in healthy subjects. Neurosci Lett 2010;485:194-7.
142. Oswald LM, Zandi P, Nestadt G, Potash JB, Kalaydjian AE, Wand GS. Relationship between cortisol responses to stress and personality. Neuropsychopharmacology 2006;31:1583-91.
143. Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, Willour VL, et al. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 2010;151:4332-43.
144. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, et al. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 2011;36:1982-91.
145. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008;299:1291-305.
146. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 2010;35:1674-83.
147. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 2013;16:33-41.
148. Scharf SH, Liebl C, Binder EB, Schmidt MV, Müller MB. Expression and regulation of the Fkbp5 gene in the adult mouse brain. PLoS One 2011;6:e16883.
149. Touma C, Gassen NC, Herrmann L, Cheung-Flynn J, Büll DR, Ionescu IA, et al. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry 2011;70:928-36.
150. O'Leary JC 3rd, Dharia S, Blair LJ, Brady S, Johnson AG, Peters M, et al. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS One 2011;6:e24840.
151. Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD, Wolf M, et al. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 2012;62:332-9.
152. Hartmann J, Wagner KV, Dedic N, Marinescu D, Scharf SH, Wang XD, et al. Fkbp52 heterozygosity alters behavioral, endocrine and neurogenetic parameters under basal and chronic stress conditions in mice. Psychoneuroendocrinology 2012;37:2009-21.
153. Petrovich E, Asher C, Garty H. Induction of FKBP51 by aldosterone in intestinal epithelium. J Steroid Biochem Mol Biol 2014;139:78-87.
154. Li XJ, Luo XQ, Han BW, Duan FT, Wei PP, Chen YQ. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer 2013;109:2189-98.
155. Zhou G, Golden T, Aragon IV, Honkanen RE. Ser/Thr protein phosphatase 5 inactivates hypoxiainduced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem 2004;279:46595-605.
156. Kumar P, Mark PJ, Ward BK, Minchin RF, Ratajczak T. Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001;284:219-25.
157. Kumar P, Ward BK, Minchin RF, Ratajczak T. Regulation of the Hsp90-binding immunophilin, cyclophilin 40, is mediated by multiple sites for GA-binding protein (GABP). Cell Stress Chaperones 2001;6:78-91.
158. Pearson JD, Mohammed Z, Bacani JT, Lai R, Ingham RJ. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein. BMC Cancer 2012;12:229.
159. Yokoi H, Shimizu Y, Anazawa H, Lefebvre CA, Korneluk RG, Ikeda JE. The structure and complete nucleotide sequence of the human cyclophilin 40 (PPID) gene. Genomics 1996;35:448-55.
160. Sanchez ER. Hsp56: a novel heat shock protein associated with untransformed steroid receptor complexes. J Biol Chem 1990;265:22067-70.
161. Scammell JG, Hubler TR, Denny WB, Valentine DL. Organization of the human FK506-binding immunophilin FKBP52 protein gene (FKBP4). Genomics 2003;81:640-3.
162. Daikoku T, Tranguch S, Friedman DB, Das SK, Smith DF, Dey SK. Proteomic analysis identifies immunophilin FK506 binding protein 4 (FKBP52) as a downstream target of Hoxa10 in the periimplantation mouse uterus. Mol Endocrinol 2005;19:683-97.
163. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000;97:3260-5.
164. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987;47:6517-21.
165. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, et al. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 2011;25:1527-38.
166. Kang H, Sayner SL, Gross KL, Russell LC, Chinkers M. Identification of amino acids in the tetratricopeptide repeat and C-terminal domains of protein phosphatase 5 involved in autoinhibition and lipid activation. Biochemistry 2001;40:10485-90.
167. Connarn JN, Assimon VA, Reed RA, Tse E, Southworth DR, Zuiderweg ER, et al. The molecular chaperone Hsp70 activates protein phosphatase 5 (PP5) by binding the tetratricopeptide repeat (TPR) domain. J Biol Chem 2014;289:2908-17.
168. Carrello A, Allan RK, Morgan SL, Owen BA, Mok D, Ward BK, et al. Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70. Cell Stress Chaperones 2004;9:167-81.
169. Das AK, Cohen PW, Barford D. The structure of the tetratricopeptide repeats of protein phosphatase 5: implications for TPR-mediated protein-protein interactions. EMBO J 1998;17:1192-9.
170. Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, Bartunik H, et al. Structure of TPR domainpeptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000;101:199-210.
171. Ward BK, Allan RK, Mok D, Temple SE, Taylor P, Dornan J, et al. A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem 2002;277:40799-809.
172. Cliff MJ, Harris R, Barford D, Ladbury JE, Williams MA. Conformational diversity in the TPR domainmediated interaction of protein phosphatase 5 with Hsp90. Structure 2006;14:415-26.
173. Cliff MJ, Williams MA, Brooke-Smith J, Barford D, Ladbury JE. Molecular recognition via coupled folding and binding in a TPR domain. J Mol Biol 2005;346:717-32.
174. Sekine Y, Hatanaka R, Watanabe T, Sono N, Iemura S, Natsume T, et al. The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1 activation by suppressing PP5. Mol Cell 2012;48:692-704.
175. Yamaguchi F, Umeda Y, Shimamoto S, Tsuchiya M, Tokumitsu H, Tokuda M, et al. S100 proteins modulate protein phosphatase 5 function: a link between CA2+ signal transduction and protein dephosphorylation. J Biol Chem 2012;287:13787-98.
176. Shimamoto S, Kubota Y, Tokumitsu H, Kobayashi R. S100 proteins regulate the interaction of Hsp90 with Cyclophilin 40 and FKBP52 through their tetratricopeptide repeats. FEBS Lett 2010;584:1119-25.
177. Shimamoto S, Takata M, Tokuda M, Oohira F, Tokumitsu H, Kobayashi R. Interactions of S100A2 and S100A6 with the tetratricopeptide repeat proteins, Hsp90/Hsp70-organizing protein and kinesin light chain. J Biol Chem 2008;283:28246-58.
178. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006;396:201-14.
179. Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, Nishitoh H, et al. Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J 2001;20:6028-36.
180. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011;7:818-26.
181. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76.
182. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004;15:651-62.
183. Azad AA, Zoubeidi A, Gleave ME, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol 2015;12:26-36.
184. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26(5A):3409-16.
185. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
186. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823:742-55.
187. Travers J, Sharp S, Workman P. HSP90 inhibition: twopronged exploitation of cancer dependencies. Drug Discov Today 2012;17:242-52.
188. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000;92:242-8.
189. Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol 2011;6:800-7.
190. Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 2010;70:27-36.
191. Ardi VC, Alexander LD, Johnson VA, McAlpine SR. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins. ACS Chem Biol 2011;6:1357-66.
192. McConnell JR, Alexander LA, McAlpine SR. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg Med Chem Lett 2014;24:661-6.
193. Estébanez-Perpiñá E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A 2007;104:16074-9.
194. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A 2011;108:11878-83.
195. Moore TW, Mayne CG, Katzenellenbogen JA. Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 2010;24:683-95.
196. Joseph JD, Wittmann BM, Dwyer MA, Cui H, Dye DA, McDonnell DP, et al. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci U S A 2009;106:12178-83.
197. Galat A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets- functions. Curr Top Med Chem 2003;3:1315-47.
198. Wang P, Heitman J. The cyclophilins. Genome Biol 2005;6:226.
199. Hoffmann K, Kakalis LT, Anderson KS, Armitage IM, Handschumacher RE. Expression of human cyclophilin-40 and the effect of the His141->Trp mutation on catalysis and cyclosporin A binding. Eur J Biochem 1995;229:188-93.
200. Ratajczak T, Carrello A, Minchin RF. Biochemical and calmodulin binding properties of estrogen receptor binding cyclophilin expressed in Escherichia coli. Biochem Biophys Res Commun 1995;209:117-25.
201. Gaali S, Kozany C, Hoogeland B, Klein M, Hausch F. Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands. ACS Med Chem Lett 2010;1:536-9.
202. Blackburn EA, Walkinshaw MD. Targeting FKBP isoforms with small-molecule ligands. Curr Opin Pharmacol 2011;11:365-71.
203. Bracher A, Kozany C, Hähle A, Wild P, Zacharias M, Hausch F. Crystal structures of the free and ligandbound FK1-FK2 domain segment of FKBP52 reveal a flexible inter-domain hinge. J Mol Biol 2013;425:4134-44.
204. Gopalakrishnan R, Kozany C, Gaali S, Kress C, Hoogeland B, Bracher A, et al. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52. J Med Chem 2012;55:4114-22.
205. Gaali S, Gopalakrishnan R, Wang Y, Kozany C, Hausch F. The chemical biology of immunophilin ligands. Curr Med Chem 2011;18:5355-79.
206. Schmidt MV, Paez-Pereda M, Holsboer F, Hausch F. The prospect of FKBP51 as a drug target. ChemMedChem 2012;7:1351-9.
207. Zheng Q, Cai X, Tan MH, Schaffert S, Arnold CP, Gong X, et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. Biotechniques 2014;57:115-24.
208. Calderwood SK. Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) 2013;2013:217513.
209. Schmid AB, Lagleder S, Gräwert MA, Röhl A, Hagn F, Wandinger SK, et al. The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J 2012;31:1506-17.
210. Koulov AV, LaPointe P, Lu B, Razvi A, Coppinger J, Dong MQ, et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell 2010;21:871-84.
211. Retzlaff M, Hagn F, Mitschke L, Hessling M, Gugel F, Kessler H, et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell 2010;37:344-54.
212. Karagöz GE, Duarte AM, Ippel H, Uetrecht C, Sinnige T, van Rosmalen M, et al. N-terminal domain of human Hsp90 triggers binding to the cochaperone p23. Proc Natl Acad Sci U S A 2011;108:580-5.